Staudinger, Heribert - Resultados de la búsqueda - Depósito Digital de Documentos de la UAB

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros

Artículos	Encontrados 1 registros

13 p, 409.0 KB

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis / Worm, Margitta ; Simpson, Eric L. (Oregon Health & Science University, Portland) ; Thaçi, Diamant (University of Lübeck, Germany) ; Bissonnette, Robert (Innovaderm Research (Montreal, Canadà)) ; Lacour, Jean Philippe (Nice University Hospital (Niça, França)) ; Beissert, Stefan (Technische Universität Dresden, Germany) ; Kawashima, Makoto (Tokyo Women's Medical University, School of Medicine, Tokyo, Japan) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Smith, Catherine H. (King's College London) ; Beck, Lisa (University of Rochester Medical Center, New York) ; Chan, Kuo-Chen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Chen, Zhen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Akinlade, Bolanle (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Hultsch, Thomas (Sanofi Genzyme, Cambridge, Massachusetts) ; Staudinger, Heribert (Sanofi, Bridgewater, New Jersey) ; Gadkari, Abhijit (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Eckert, Laurent (Sanofi, Chilly-Mazarin, France) ; Davis, John D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Rajadhyaksha, Manoj (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Graham, Neil M. H. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Pirozzi, Gianluca (Sanofi, Bridgewater, New Jersey) ; Stahl, Neil (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Yancopoulos, George D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Ardeleanu, Marius (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Universitat Autònoma de Barcelona. Departament de Medicina
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. [...]
2019 - DOI (Digital Object Identifier)

10.1001/jamadermatol.2019.3617
JAMA Dermatology, Vol. 156 (december 2019) , p. 131-143

Registro completo -

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.